76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Eli Lilly and Co.
Closed
SectorHealthcare
764.43 -0.25
Overview
Share price change
24h
Min
753
Max
768.08
Income | -6.1B 2.8B |
|---|---|
Sales | -804M 13B |
P/E Sector Avg | 60.989 51.198 |
EPS | 3.34 |
Dividend yield | 0.8 |
Profit margin | 21.678 |
Employees | 47,000 |
EBITDA | -2B 4.2B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +33.67% upside |
Dividend yield Sector Avg | 0.80% 2.40% |
|---|---|
Next Earnings | 6 Aug 2025 |
Next Dividend date | 10 Jun 2025 |
Next Ex Dividend date | 14 Aug 2025 |
Market Cap | -157B 671B |
|---|---|
Previous open | 764.68 |
Previous close | 764.43 |
News Sentiment
By Acuity
34%
66%
112 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Eli Lilly and Co. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Eli Lilly and Co. Forecast
Price Target
By TipRanks
33.67% upside
12 Months Forecast
Average 1,003.6 USD 33.67%
High 1,190 USD
Low 700 USD
Based on 19 Wall Street analysts offering 12 month price targets forEli Lilly and Co. - Dist in the last 3 months.
Sentiment
By Acuity
112 / 380 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Eli Lilly and Co.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
